Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice.

Details

Serval ID
serval:BIB_A4E833D2057F
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice.
Journal
Melanoma research
Author(s)
Mangana J., Zihler D., Bossart S., Brönnimann D., Zachariah R., Gérard C.L.
ISSN
1473-5636 (Electronic)
ISSN-L
0960-8931
Publication state
Published
Issued date
01/10/2022
Peer-reviewed
Oui
Volume
32
Number
5
Pages
366-372
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
Cutaneous melanoma represents a major cause of cancer death in Europe. Without adequate therapy, the 5-year survival rate is 15-20% in distant metastatic disease. Evaluating the status quo of treatment standards in advanced melanoma and rationale for therapy decisions in Switzerland between January 2016 and September 2018. In this retrospective, anonymized registry, data of male and female patients with unresectable advanced/metastatic BRAF-positive cutaneous melanoma treated in first-, second- and third-line with registered substances were analyzed using descriptive statistics. Forty-one patients (56.1% male) were included providing a total of 70 treatment lines (first-line: n = 41; second-line: n = 18; and third-line: n = 11). Within the patients presenting with stage III or IV melanoma, immunotherapy with checkpoint inhibitors was more frequently administered as first-line treatment than targeted therapy (TT) (70.7% vs. 29.3%). Across all lines, patients received TT in 47.1% (predominantly combined BRAF-MEK-inhibition) and immunotherapy in 52.9% of the cases (anti-PD-1 monotherapy in 62.2% and anti-PD-1/anti-CTLA-4 combinations in 37.8%). Most commonly, the treatment type was switched from TT to immunotherapy or vice versa upon disease progression. The most frequent rationales for prescribing either TT or immunotherapy were physician's preference (40.0%) or remission pressure (28.6%), respectively. Disease progression led to treatment discontinuation more frequently than undesired events. Patients in Switzerland with unresectable advanced or metastatic BRAF-mutant melanoma predominantly receive guideline-recommended treatments. IO was used as predominant front-line therapy, with TT/immunotherapy switch being the predominant treatment principle. Sequencing studies are underway to identify the optimal treatment regimen for those patients. 32: 366-372 Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Keywords
Disease Progression, Female, Humans, Male, Melanoma/drug therapy, Melanoma/genetics, Neoplasms, Second Primary/chemically induced, Programmed Cell Death 1 Receptor, Protein Kinase Inhibitors/therapeutic use, Proto-Oncogene Proteins B-raf/genetics, Retrospective Studies, Skin Neoplasms/chemically induced, Skin Neoplasms/drug therapy, Skin Neoplasms/genetics, Switzerland, Melanoma, Cutaneous Malignant
Pubmed
Web of science
Create date
26/07/2022 12:19
Last modification date
19/12/2023 7:14
Usage data